Physician profile
Daniel Temple
NPI 1093167520
$727.42
in general payments reported to CMS, 2019-2025
10 companies · $727 in 2025
The $727 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $157.38 | 2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $102.36 | 2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $96.98 | 2025 | Mounjaro, Zepbound, Kisunla |
| Astellas Pharma US INC | $87.41 | 2025 | Veozah |
| Pfizer INC. | $68.75 | 2025 | |
| Abbott Laboratories | $65.99 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $62.86 | 2025 | |
| Ardelyx, INC. | $31.50 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $29.38 | 2025 | Shingrix, Arexvy |
| Dexcom, INC. | $24.81 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Temple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.